Home › lilly
 

Keywords :   


Tag: lilly

Eli Lilly and Given Consensus Rating of "Buy" by Analysts

2015-11-27 21:23:53| Agriculture - Topix.net

Shares of Eli Lilly and have earned a consensus recommendation of "Buy" from the twenty-one analysts that are presently covering the firm, ARN reports . Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company.

Tags: buy rating consensus eli

 

Morningstar Gives AA Credit Rating to Eli Lilly and

2015-11-25 10:43:05| Agriculture - Topix.net

Eli Lilly and has received an "AA" credit rating from analysts at Morningstar . The investment research firm's "AA" rating indicates that the company is a very-low default risk.

Tags: and rating credit eli

 
 

Drug maker Eli Lilly and Co.'s headquarters are in Indianapolis.

2015-11-25 00:20:54| Agriculture - Topix.net

New Eli Lilly cancer drug approved by FDA Biologic drug is aimed at countering hard-to-treat lung cancer Check out this story on IndyStar.com: http://indy.st/1HlaaUX Eli Lilly and Co. won federal marketing approval for a new drug proven to extend the lives of people battling a hard-to-treat lung cancer.

Tags: in drug maker cos

 

Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial

2015-11-19 12:30:12| Merck.com - Research & Development News

Dateline City: INDIANAPOLIS and KENILWORTH, N.J. INDIANAPOLIS and KENILWORTH, N.J. Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lillys ALIMTA (pemetrexed for injection) and Mercks KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Language: English read more

Tags: iii cell trial expand

 

Eli Lilly and Upgraded to Outperform at BMO Capital Markets

2015-11-16 13:36:23| Agriculture - Topix.net

The firm currently has a $100.00 price objective on the stock, up from their prior price objective of $90.00. BMO Capital Markets' price target points to a potential upside of 25.71% from the stock's previous close.

Tags: capital markets eli upgraded

 

Sites : [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] next »